The market is gradually moving toward personalized treatment strategies based on kidney function, albuminuria, cardiovascular risk, diabetes status, and comorbidities. Treatment selection increasingly considers both efficacy and safety across different stages of CKD. This approach is encouraging development of more targeted therapeutic and monitoring solutions. The Diabetic Nephropathy Market...